CCR2 and craniosynostosis: While no significant changes in F4/80+ (wmφ), Ly6G (PMN), or Treg (CD4+ CD25+) cell populations were noted in the CSO treated group, a significant reduction in pro-inflammatory monocytes (CCR2+Ly6Chi cells) was observed following CSO treatment (Fig. S1).